1. Introduction
===============

Natural botanical products have a long history in the world and are featured in using a complex combination of herbs to treat various diseases (e.g. rheumatoid arthritis, menopausal symptoms, colds and flu etc). CKBM-A01 is a combination of herbs including Wu Wei Zi (*Schisandrachinensis*), Ginseng (*Panaxginseng*), Hawthorn (*Fructus Crataegi*), Jujube (*Ziziphusjujube*), Soybean (*Glycine Max*) and *Saccharomyces cerevisiae* (baker\'s yeast), which is formulated based on traditional Chinese medicinal principles and processed by a proprietary technology developed by CK Life Sciences Limited (CKLS).

*Schisandrachinensis* has been shown to suppress the TPA-induced skin tumor formation and prostate carcinogenesis [@B1], [@B2]. It also aids to protect liver from injury, stimulates liver regeneration and reduces inflammation. *Panaxginseng* and *Ziziphusjujube* provide several pharmacological activities like modulating immune system and anti-stress activities [@B3]. The levels of cytokines (e.g. tumor necrosis factor-α, IL-1β, IL-6, interferon-γ) and reactive oxygen/nitrogen production were enhanced by these compounds to exert phagocytic activity [@B4]. Isoflavone-containing compound like soybean has been shown to lower estrogen levels, which helps to prevent and reduce the risk of breast cancer [@B5]. In addition, extracts of soybean suppressed F3II mouse mammary adenocarcinoma cell growth in vivo and in vitro through the G~2~/M cell cycle arrest [@B6].

In this study, we aimed to determine the effect of CKBM-A01 (a combined recipe of the above mentioned Chinese herbs and yeast) on the growth of human gastric cancer using a unique subcutaneous implantation model of gastric cancer tissue. In this connection, CKBM was given at different doses to investigate the effect on tumor growth. To further examine the anti-tumor mechanism, the three important biological parameters in tumorigenesis including cell proliferation and apoptosis [@B7], and also angiogenesis [@B8] were assessed in gastric tumors after drug treatment.

2. Materials and methods
========================

*Chemicals and reagents*
------------------------

CKBM-A01 (Batch no.: 0212201) was provided by CKLS (Hong Kong, China). The product is in liquid form. All chemicals and reagents were purchased from Sigma (Sigma Chemical Company, St Louis, USA) unless otherwise specified.

*Cell culture*
--------------

Human gastric carcinoma cell line (MKN-28) was purchased from RIKEN (The Institute of Physical and Chemical Research) Cell Bank, Japan. Cells were cultured in RPMI 1640 medium (GibcoBRL, USA) supplemented with 10% fetal bovine serum (BibcoBRL), 100 U/mL penicillin G, 100 µg/mL streptomycin, and maintained in a humidified 5% CO~2~ atmosphere at 37ºC.

*Experimental animals and tumor implantation*
---------------------------------------------

Female athymic balb/c nude mice (Charles River Laboratories Ltd., USA), aged 4-6 weeks and weighing 19-24 g, were used in the tumor implantation model. They were housed in IVC cages of isolated ventilation to avoid microbial contamination. Gastric cancer tissues (1.5 mm^3^) were implanted subcutaneously (s.c.) into the right dorsal area of mice. Ten days after implantation, animals were randomized into 4 treatment groups: control group (0.8 ml distilled water/mouse) and CKBM-A01 (0.2, 0.4 or 0.8 ml/mouse) treatment groups. They were fed intragastrically (i.g.) daily for 14 and 28 days.

Tumor areas were measured every 7 days using a caliper, and the tumor area was calculated according to the formula: tumor volume (mm^3^) = *d*^2^ x *D*/2, where *d* and *D* were the shortest and the longest diameter respectively [@B9].

*Assessment of cell proliferation*
----------------------------------

Paraffin-embedded tumor samples that had been fixed in formalin were cut into sections of 5 μm. Sections were incubated in citrate buffer (0.01 M, pH 6.0) at 80ºC for 15min and followed by digestion using pepsin (0.005%) in HCl (0.01 N, pH 2.0). After washing with PBS (0.01 M, pH 7.4), sections were incubated with normal serum (LSAB kit, DAKO, Copenhagan, Denmark) for 60 min. After blocking, they were incubated with a monoclonal primary antibody against mouse proliferating cell nuclear antigen (PCNA, 1:200) (Santa Cruz Biotechnology, Santa Cruz) for 90 min, and then incubated with Link reagent (LSAB kit, DAKO) for 60 min at room temperature. Sections were incubated with Streptavadin (LSAB kit, DAKO) for 60 min, and further incubated with hydrogen-peroxidase-diaminobenzidine (H~2~O~2~-DAB) to visualize the PCNA-positive cells. Finally, they were counterstained with Mayer\'s hematoxylin. The total number of proliferating cells in a total of ten fields (x 400) across and perpendicular at the center of the tumor was counted under the microscope. The results of cell proliferation were expressed as the number of PCNA-positive cells per field [@B10]. The same approach was adopted for measuring apoptosis and angiogenesis in the tumors.

*Assessment of angiogenesis*
----------------------------

Microvessel density was assessed by immunostaining as described previously [@B11] with modifications. Sections were digested with trypsin for 30 min at room temperature and incubated with a blocking agent (LSAB kit, DAKO, Copenhagen, Denmark) for 1 hr. They were then incubated with a rabbit anti-human von Willebrand factor (DAKO, Copenhagan, Denmark) with a dilution of 1:200 overnight at 4ºC. After washing with PBS (0.01 M, pH 7.4), sections were incubated with Link reagent (LSAB kit, DAKO) for 1 hr, followed by streptavidin (LSAB kit, DAKO) for another 1 hr. Sections were incubated with hydrogen-peroxidase-diaminobenzidine to visualize the microvessels. The results of microvessel density were expressed as the number of microvessel per field (x 200).

*Assessment of apoptosis*
-------------------------

Epithelial cell apoptosis was detected from paraffin-embedded tissue sections by the terminal deoxynucleotidyltranferase-mediated dUTP nick end--labeling (TUNEL) method as described previously [@B12]. Tissue sections were digested with 20 µg/ml proteinase K for 20 min at 37ºC and treated with 0.3% H~2~O~2~ solution at room temperature. Afterwards, they were incubated with TdT buffer containing 40 U/ml TdT and 5 nmol/ml biotinylated-dUTP, and kept in humidified atmosphere for 90 min at 37ºC. The reaction was quenched by washing with terminating buffer (300 mM sodium chloride and 30 mM sodium citrate) for 15 min. After blocking with normal serum, sections were incubated with peroxidase-labeled streptavidin for 30 min and stained with diaminobenzidine-H~2~O~2~ for 10 min. Finally, the sections were counterstained with Mayer\'s hematoxylin. For positive control, sections were treated with 0.5 U/ml DNase I in Dnase buffer (10 mM NaCl, 50 mM MnCl~2~, 0.1 mM CaCl~2~, 25 mM KCl and 10 mM Tris-HCl, pH 7.4) for 10 min; whereas negative control was prepared with the omission of TdT. The number of apoptotic cells in a total of ten fields (x 400) per tumor was counted under microscope. The results of apoptotic cells were expressed as the number of apoptotic cells per field.

*Statistical analysis*
----------------------

Statistical significance between the treatment groups was analyzed using a two-way statistical analysis of variance (ANOVA), followed by Dunnett t-test and post-hoc analysis when necessary.

3. Results
==========

*Effect of CKBM treatment on gastric tumor growth*
--------------------------------------------------

All the control (water vehicle-treated) and CKBM-treated mice developed subcutaneous tumor after gastric cancer tissue implantation. Figures [1](#F1){ref-type="fig"}A & [1](#F1){ref-type="fig"}B show the effect of CKBM on tumor growth 14 days or 28 days after treatment. The tumor growth of the control group increased steadily during the 14- and 28-day experimental periods. Results showed that CKBM exhibited a dose-dependent inhibition on tumor growth starting from Day 7 onwards. There was a significant 50% reduction on tumor growth in the CKBM-treated groups at doses of 0.4 and 0.8 ml/mouse on Day 21 and Day 28 after drug treatment (Figure [1](#F1){ref-type="fig"}B) when compared with the corresponding control group. CKBM did not affect the body weight changes in these animals during the experimental period.

*Effect of CKBM treatment on angiogenesis in gastric tumors*
------------------------------------------------------------

There was an increase in the microvessel density from Day 14 to Day 28 in the control group, implicating that angiogenesis is essential in the development of tumors (Figures [2](#F2){ref-type="fig"}A & [2](#F2){ref-type="fig"}B). However, CKBM treatment for 14 and 28 days did not produce dose-dependent effect on angiogenesis in gastric tumors. Notably, CKBM at all doses, except 0.4 ml/mouse, significantly increased angiogenesis in gastric tumors after 14 days of drug treatment (Figure [2](#F2){ref-type="fig"}A). In contrary, the stimulatory effect of CKBM on angiogenesis was not observed after 28 days of treatment although the highest dose of CKBM (0.8 ml/mouse) had a trend of decrease in angiogenesis but did not have statistical significance (Figure [2](#F2){ref-type="fig"}B).

*Effect of CKBM treatment on apoptosis of cancer cells in gastric tumors*
-------------------------------------------------------------------------

There was no significant effect on the number of apoptotic cells in the gastric tumors after 14 days of drug treatment (Figure [3](#F3){ref-type="fig"}A). However, prolonged treatment of CKBM to 28 days dose-dependently exhibited an induction of apoptosis in gastric cancer cells. At doses of 0.4 and 0.8 ml/mouse of CKBM treatment, apoptosis was significantly increased by 76% and 97% respectively when compared with the corresponding control group (Figure [3](#F3){ref-type="fig"}B).

*Effect of CKBM treatment on cell proliferation of cancer cells in gastric tumors*
----------------------------------------------------------------------------------

The anti-proliferative effect of CKBM treatment was observed as early as 14 days after drug treatment. The highest dose of 0.8 ml/mouse significantly reduced the number of cell proliferation in the gastric tumors by 30% when compared with the control group (Figure [4](#F4){ref-type="fig"}A). Similarly, prolong treatment of CKBM to 28 days dose-dependently inhibited the number of proliferative cells in gastric tumors (Figure [4](#F4){ref-type="fig"}B).

4. Discussion
=============

In this study, CKBM significantly inhibited the growth of gastric tumor in human xenografts model using MKN-28 cells (Figures [1](#F1){ref-type="fig"}A & [1](#F1){ref-type="fig"}B). The efficacy of CKBM exhibited a dose-dependent manner in this ex-vivo model during the 28-day experimental period and exerted the inhibitory action as early as 21 days after drug treatment (Figure [1](#F1){ref-type="fig"}B). The effective doses of CKBM were found to be 0.4 and 0.8 ml/mouse, which significantly reduced the number of PCNA-positive cells and increased the apoptotic cells in the tumor tissues (Figures [3](#F3){ref-type="fig"}B & [4](#F4){ref-type="fig"}B). In contrast, CKBM did not affect angiogenesis at the time when it inhibited tumor growth (Figures [2](#F2){ref-type="fig"}A & [2](#F2){ref-type="fig"}B), although it increased with time along with tumor development in the control group. These findings implicated that CKBM suppressed gastric cancer growth specifically through the reduction of cell proliferation and promotion of apoptosis in this model.

Dietary supplement containing *Schisandra chinensis* has been shown to reduce prostate cancer cell growth and induce apoptosis by inhibiting androgen receptor expression [@B1]. Besides, soybeans contain various anti-carcinogenic compounds including lunasin and lectins that were shown to induce apoptosis in malignant cells [@B13]. As CKBM contains these compounds, this would partially explain why it inhibits tumor growth in the present animal model. Besides, CKBM may also inhibit cancer xenograft growth via cytokine secretion. *Panaxginseng*and *Ziziphusjujube*, the other major components in CKBM, induce cytokine release in macrophages [@B4]. Moreover, soluble β-glucans from *Saccharomyces cerevisiae* could activate macrophage to secrete TNF-α [@B14], which is found to have a pro-apoptotic effect on human cancer cells [@B15]. Anti-cancer drugs such as sulindac and its metabolite have been shown to augment TNF-α-mediated cell death signaling pathway through the blockade of NF-κB in human carcinoma cells [@B16]. Previous study also shows that CKBM is able to modulate the immune response through the induction of TNF-α and IL-6 secretion in peripheral blood mononuclear cells [@B17]. Although nude mice are immune deficient animals, there is evidence that cytokines are inducible in these animals. To this end, previous studies show that TNF-α can be induced and detected in the serum and splenocytes from nude mice after drug treatment such as 5-FU [@B18], [@B19], [@B20]. It is therefore possible that CKBM could induce cytokine release including TNF-α in these animals and inhibit tumor growth. However, further study is needed to determine how they are induced and the mechanisms they inhibit cancer cell growth in *vivo.*

In summary, CKBM is a mixture of natural herbs and yeast that is effective to reduce the growth of gastric tumors in nude mice. The anti-tumorigenic action of CKBM is perhaps through the induction of apoptosis and inhibition of proliferation of gastric cancer cells. However, further clinical trials in humans are needed to examine the pharmacokinetics and the therapeutic action of CKBM on cancer patients.
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